Mark Manfredi is the founder of DISCO Pharmaceuticals. DISCO Pharmaceuticals has raised $38M in total funding. Latest round: Seed.
Mark Manfredi, Ph.D., is the CEO of DISCO Pharmaceuticals, a company focused on developing novel surfaceome-targeted therapies for challenging tumors. The company recently closed a €36 million seed financing round to advance its pipeline. Prior to DISCO, Manfredi served as CEO of Ikena Oncology and was an Entrepreneur in Residence at Atlas Venture. He also held roles as Chief Scientific Officer at Raze Therapeutics and Vice President, Oncology Biology at Takeda Pharmaceuticals.
Full founder directory · Investor directory · Company funding database · Fundraising library